Since the original discovery of RKIP in 1999, and its unique molecule to interact and inhibit the Raf/Mek/Erk signaling and protumorigenic pathway, significant new findings were reported of the pleotropic activities RKIP play in normal and several diseases particularly in cancers. Here, RAF1 is linked to cancer.